American Society of Clinical Psychopharmacology (ASCP)

AXS-05 | Alzheimer’s Disease-Related Agitation

Clinical Profile of AXS-05 (Dextromethorphan-Bupropion) in Treating Alzheimer’s Disease Agitation: Results From The Phase 2/3 Development Program

Dr. Jeffrey L. Cummings, MD, ScD describes the "Clinical Profile of AXS-05 (Dextromethorphan-Bupropion) in Treating Alzheimer’s Disease Agitation: Results From The Phase 2/3 Development Program" ASCP 2024 poster

AXS-05 | Major Depressive Disorder

Real-World Auvelity® (AXS-05) Patient Characteristics in Major Depressive Disorder

Dr. Andrew Muzyk, PharmD describes the "Real-World Auvelity® (AXS-05) Patient Characteristics in Major Depressive Disorder" ASCP 2024 poster

AXS-05 | Alzheimer’s Disease-Related Agitation

Effects of AXS-05 (Dextromethorphan-Bupropion) in Improving Anhedonia and Interest-Activity Symptoms of MDD and the Associated Improvements in Functional Impairment

Dr. Roger McIntyre, MD, FRCPC describes the "Effects of AXS-05 (Dextromethorphan-Bupropion) in Improving Anhedonia and Interest-Activity Symptoms of MDD and the Associated Improvements in Functional Impairment" ASCP 2024 poster

Solriamfetol | Excessive Daytime Sleepiness

Solriamfetol Improves Cognitive Performance in Preclinical Models of Sleep Apnea and in a Randomized Placebo-Controlled Study of Sleep Apnea Participants (SHARP)

Dr. David Gozal, MD, MBA describes the "Solriamfetol Improves Cognitive Performance in Preclinical Models of Sleep Apnea and in a Randomized Placebo-Controlled Study of Sleep Apnea Participants (SHARP)" ASCP 2024 poster